
Diabetic Retinopathy
Latest News
CME Content


A study including data from about 42,000 eyes found diabetic retinopathy (DR) severity is a risk factor for the progression of diabetic eye disease. Other findings support the idea that genetic factors influence the development of proliferative DR versus diabetic macular edema.

Study highlights the role of demographic and socioeconomic characteristics as contributors to disease- and treatment-related disparities among patients with diabetic macular edema.

Challenges to diabetes management

Treatment options for DR/DME

ADA guidelines for DR/DME management

Diabetes management: Communication between ODs and MDs

Optimizing diabetes health management

Use of OCT-A for patients with diabetes

Imaging for diabetic retinopathy

Overview of diabetic eye disease

Integrating AI to manage DR in a primary care setting
Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.

Updates in DME, diabetic retinopathy
A panel of experts in ophthalmology and optometry review the diagnosis and treatment of diabetic eye disease including emerging agents in the field.

Exploring pathogenic cytokines as biomarkers for DME
Results support further research investigating transforming growth factor-β-Induced Gene Human Clone 30 (BIGH3).

Aflibercept broadly effective for reducing DR severity in post-hoc analysis
The benefit is robust across a variety of demographics and baseline disease characteristics, according to data.

Researchers advocate for intraoperative intravitreal steroid during cataract surgery in DME eyes
Study offers a real-world scenario of a very specific, but frequent and crucial aspect of the care of patients with diabetes, suggests clinician

Probe of IRIS Registry shows anti-VEGF injections leading treatment for PDR
Visual acuity outcomes at 6 months’ post-treatment were similar, regardless of the use of anti-VEGF therapy.

FA implant outperforms anti-VEGF in DR patients lost-to-follow-up
Results could provide a new preferred treatment paradigm for this population

Identifying biomarkers to predict diabetic retinopathy progression
Study explores correlations between functional and structural tests

AMD, DED most common retinal conditions in the United States
The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.

Reductions in macular retinal nonperfusion after anti-VEGF treatment with aflibercept are correlated with improvements in BCVA and central retinal thickness in patients with DR/DME, according to a post-hoc analysis of the VISTA dataset, said Charles C. Wykoff, MD, PhD, during ARVO 2020.

ASRS 2020: Diabetic retinopathy progression in anti-VEGF versus FA implant
Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.

Study explores mental health issues in patients with diabetic retinopathy
Rates of anxiety and depression increased but were not necessarily tied to disease severity

Considering ethnicity-related differences in macular thickness among diabetics
A retrospective study found that in both patients with type 2 diabetes and non-diabetics, average central macular thickness was lower in Asians than Caucasians. Why is this significant for clinicians?

Identifying risk factors for severe diabetic eye disease
An analysis using a large commercial claims database found that almost 3% of patients developed severe diabetic eye disease within 5 years of being diagnosed with type 2 diabetes. Clinical and demographic risk factors were also identified.




























